Skip to main content

Table 3 Current treatments usage in APD and non-APD patients and treatment response

From: Criteria for identification of advanced Parkinson’s disease: the results of the Italian subgroup of OBSERVE-PD observational study

  APD (N = 60) Non-APD (N = 80)
Current PD oral/transdermal treatments (Possible multiple answers) N = 60 N = 80
 Oral levodopa/carbidopa or benserazide 55 (92%) 60 (75%)
 Oral dopamine agonists 35 (58%) 48 (60%)
 Apomorphine patch 2 (3%) 0
 Subcutaneous apomorphine rescue injection 2 (3%) 0
 COMT-inhibitors 22 (37%) 6 (8%)
 MAO-B inhibitors 14 (23%) 41 (51%)
 Amantadine 6 (10%) 6 (8%)
 Missing 2 (3%) 0
Current oral/transdermal treatment for PD N = 60 N = 80
 Patients on only oral/transdermal therapy 40 (67%) a 79 (99%)
 Patients on ongoing DAT 18 (30%) 1 (1%)
 Missing 2 (3%) 0
Number of current oral/transdermal treatments N = 58 N = 80
 1 12 (21%) 21 (26%)
 2 19 (33%) 33 (41%)
 3 20 (34%) 24 (30%)
 4 4 (7%) 2 (3%)
 5 3 (5%) 0
Treatment Response on current treatment (oral/transdermal or DAT) N = 60 N = 80
 Complete response 12 (20%) a 55 (69%)
 Partial response 47 (78%) a 24 (30%)
 Too early to assess response 1 (2%) 1 (1%)
Status of DAT in the eligible patients N = 44 (73%) eligible to DAT N = 5 (6%) eligible to DAT (1 Missing)
 Ongoing DAT 18/44 (41%) 1/5 (20%)
 Decided at visit to start DAT 9/44 (20%) 0
 No DAT 17/44 (39%) 3/5 (60%)
Type of DAT on 44 eligible APD and on 5 eligible non-APD patients
 DBS 11 (25%) 1 (20%)
 LCIG 7 (16%) 0
 CSAI 0 0
Reasons APD patients were not using DAT (Possible multiple answers) N = 17  
 Age 2 (12%)  
  Patient refusal 5 (29%)  
 Patient needs more time to decide 10 (59%)  
 Cognitive related issues 2 (12%)  
 Comorbidities 2 (12%)  
  1. DAT Device Aided Therapy, DBS Deep Brain Stimulation, CSAI Apomorphine SC infusion, LCIG Levodopa-carbidopa intestinal gel, COMT (catechol-O-methyltransferase), MAOB (Monoamine oxidase type B)
  2. aP < 0.001 vs non-APD patients (Chi-square test)